micronized fenofibrate / Generic mfg. - LARVOL DELTA

Fenofibrate-associated rhabdomyolysis complicated by dialysis-requiring acute kidney injury presenting with atypical clinical manifestations: A case report and literature review. (PubMed, Medicine (Baltimore)) - "In older patients with CKD, eGFR should be calculated before fenofibrate is prescribed, and dosing should follow the product label. Unexplained renal deterioration or nonspecific symptoms after fenofibrate exposure should prompt measurement of CK and myoglobin. Immediate drug withdrawal and supportive treatment are essential, whereas IHD should be reserved for standard AKI indications."

Journal • Review • Acute Kidney Injury • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Hypertriglyceridemia • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • MB

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Lindsay Ferguson, MD | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial primary completion date • Cervical Cancer • Gynecology • Oncology • Solid Tumor

MANAGING MULTIFACTORIAL CHYLOMICRONEMIA THROUGH TEAM-BASED CARDIOMETABOLIC CARE: A REAL-WORLD CASE (ACC 2026) - "Background: Multifactorial chylomicronemia syndrome (MCS) is characterized by severe hypertriglyceridemia driven by polygenic susceptibility and secondary factors such as obesity, diet, and metabolic disease...Initial triglycerides (TG) were 1,752 mg/dL while on statin, fenofibrate micronized, icosapent ethyl, and a thiazide diuretic...Multidisciplinary adjustments included dietary reinforcement and addition of evolocumab, reducing TG to 430 mg/dL, followed by initiation of tirzepatide after complex prior authorization... Sustained MCS control requires a multifaceted, team-based approach addressing lifestyle, pharmacotherapy, and systemic challenges. Coordinated cardiometabolic care achieves lasting TG reduction and mitigates long-term cardiovascular and pancreatitis risk."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Severe Hypertriglyceridemia • Sleep Disorder

CRACKING CHYLOMICRONS THROUGH TEAMWORK: A MULTIDISCIPLINARY APPROACH TO FAMILIAL CHYLOMICRONEMIA SYNDROME (ACC 2026) - "At our clinic, coordinated optimization included icosapent ethyl 4 g daily, fenofibrate micronized 200 mg daily, and genetic testing...Olezarsen, an antisense oligonucleotide targeting apoC-III, was initiated... Team-based cardiometabolic care bridges gaps between specialties, enabling early diagnosis, precision therapy, and prevention-focused management. Such collaborative models transform outcomes in rare but high-risk conditions like functional FCS."

Cardiovascular • Dyslipidemia • Familial Chylomicronemia Syndrome • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia • APOA5

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=6 | Terminated | Sponsor: Mayo Clinic | Completed ➔ Terminated; Low Enrollment

Trial termination • Transplantation

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Lindsay Ferguson, MD | Suspended ➔ Recruiting

Enrollment open • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: Lindsay Ferguson, MD | Recruiting ➔ Suspended

Trial suspension • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Hypercholesterolemia management in a patient with mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes (NLA 2025) - "However, one case study in a patient with mitochondrial myopathy due to heteroplasmic mitochondrial DNA missence mutation in MTCO1 gene (m.7671T>A) demonstrated stable CK levels without recurrence of myalgia while taking alirocumab 75 mg every 2 weeks, ezetimibe 10 mg daily, marine omega 3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days (Cicero et al., 2020)...He had a history of hypercholesterolemia with debilitating myalgias on simvastatin, atorvastatin and rosuvastatin prior to MELAS diagnosis...Ezetimibe 10 mg daily and icosapent ethyl 4 g daily was initiated and well tolerated...Evolocumab 140 mg subcutaneous every 14 days was prescribed and tolerated without side effects...Conclusions This case highlights consideration for MELAS in young adults with stroke-like episodes and demonstrates successful use of non-statin lipid lowering medications to manage hypercholesterolemia. Further research is necessary in this patient population."

Clinical • Cardiovascular • CNS Disorders • Dyslipidemia • Metabolic Disorders • Musculoskeletal Pain • Myositis • Pain

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=5 | Completed | Sponsor: Mayo Clinic | Recruiting ➔ Completed | N=148 ➔ 5

Enrollment change • Trial completion • Hepatology • Transplantation

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Lindsay Ferguson, MD | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients with Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD | Trial completion date: May 2025 ➔ Nov 2026 | Initiation date: Aug 2024 ➔ Nov 2024 | Trial primary completion date: Jan 2025 ➔ Jun 2026

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD | Initiation date: Feb 2024 ➔ Aug 2024

Trial initiation date • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD

New P1 trial • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=148 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Feb 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Hepatology • Transplantation

Associates of fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. (PubMed, Diabetes Metab Res Rev) - "Insulin use and sex-specific complications (in men, macrovascular disease; in women, neuropathy) are independently associated with fragility fractures in adults with type 2 diabetes."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology • Type 2 Diabetes Mellitus

A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (AHA 2022) - P2 | "These agents have been shown to inhibit SARS-CoV-2 replication in cell culture systems in vitro. We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a double-blinded fashion. Among patients with COVID-19, fenofibrate has no significant effect on various clinically relevant outcomes."

Clinical • Diabetes • Genetic Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Respiratory Diseases • PPARA

Lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Comparison table: Some lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=148 | Recruiting | Sponsor: Mayo Clinic

New P2 trial • Hepatology • Transplantation

Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Beijing 302 Hospital; N=72 ➔ 0; Trial completion date: Jan 2019 ➔ Sep 2021; Recruiting ➔ Withdrawn; Trial primary completion date: Jan 2019 ➔ Sep 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Fibrosis • Hepatology • Immunology • Primary Biliary Cholangitis

Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - P4; N=11; Completed; Sponsor: Medical University of South Carolina; Recruiting ➔ Completed; N=40 ➔ 11; Trial completion date: Mar 2021 ➔ Mar 2020; Trial primary completion date: Dec 2020 ➔ Mar 2020

Biomarker • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Content analysis of social and economic issues in Indonesia during the COVID-19 pandemic. (PubMed, Heliyon) - "This is a descriptive quantitative study using a content analysis approach to obtain primary data from 6,376 online news articles published by Antara News from 28 February to 8 April 2020...COVID-19 is not only a global health crisis but also a major labour market and economic crisis that has had a significant impact on society. In conclusion, a broader study is recommended using several publication periods and online media."

Journal • Infectious Disease • Novel Coronavirus Disease

Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital. (PubMed, Acta Med Indones) - "Data termasuk karakteristik klinis, gejala, komorbiditas, multimorbiditas dan luaran mortalitas pasien.HasilDi populasi pasien lansia (n=44), mayoritas berusia di antara 60-69 tahun (68%), berjenis kelamin laki-laki (66%), dan tidak memiliki riwayat kontak erat dengan pasien COVID-19 sebelumnya (86%)...Atypical COVID-19 presentations are possible in older adults. We postulated that immunosenescence and sex-specific immunoregulatory function play an important role in causing death in this study cohort. Keywords: Clinical Profile, Elderly, Geriatric Patient, COVID-19, Indonesia."

Clinical • Journal • Diabetes • Geriatric Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Oncology

Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - P4; N=40; Recruiting; Sponsor: Medical University of South Carolina; Trial completion date: Sep 2020 ➔ Mar 2021; Trial primary completion date: Jun 2020 ➔ Dec 2020

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

"Ya Allah gini amat ya ini orang, gw antara pengen marah sm ngakak.. To save my self, I chose lol" (,@Mims05783653)